Approved Sunscreen UV Filters by Country

A side-by-side comparison of every permitted sunscreen filter across the US, EU, UK, South Korea, Japan, Australia, Canada, China, Brazil, and India — with maximum concentrations and current regulatory status. Compiled and maintained by Jane Yoo, MD, a board-certified dermatologist. Last updated November 6, 2026.

Sunscreen regulation is fragmented: a filter that anchors a Korean or European formula may be unavailable in the United States, capped at a different level, or on its way to a ban. This page tracks all of it in one place, across 10 regulatory markets and 52 UV filters, with primary sources cited.

10 markets at a glance

How many UV filters each regulator permits, and where each one is headed. A higher count doesn’t mean stronger protection — Japan’s total, for example, is inflated by obsolete legacy filters, while the EU and Korea lead on the modern broad-spectrum filters that matter most.

Market Regulator Filters permitted Regulatory posture
🇺🇸 United States FDA 17 → 15 in 2027 Catching up — the fewest modern UVA filters; added bemotrizinol in 2026; removing PABA & trolamine salicylate (effective Sep 2027)
🇪🇺 European Union European Commission / SCCS 29 The broadest modern list; steadily tightening older filters (oxybenzone, homosalate, 4-MBC)
🇬🇧 United Kingdom OPSS / SAG-CS 29 EU-derived but diverging post-Brexit — kept homosalate at 10%; banned 4-MBC in July 2026
🇰🇷 South Korea MFDS 32 Fast-moving — three new filters added since 2024; cutting oxybenzone
🇯🇵 Japan MHLW 35 Organic-filter list static since 2019; several Japan-only filters; ZnO/TiO₂ uncapped
🇦🇺 Australia TGA 30 Therapeutic-goods model; actively restricting oxybenzone and homosalate (2025–26)
🇨🇦 Canada Health Canada 21 Monograph model; a broad modern list including both Tinosorbs and Mexoryls
🇨🇳 China NMPA 26 Aligning toward the EU — phased restrictions on 4-MBC, oxybenzone, homosalate (2027–28)
🇧🇷 Brazil ANVISA 35 Very permissive (Mercosur-harmonized) — still allows PABA and 4-MBC alongside all modern filters
🇮🇳 India CDSCO / BIS 29 29 filters under IS 4707 (Part 4):2022; primary text not read, summarized from a secondary source — modern filters permitted; sunscreens are cosmetics

Methods and snapshot (verified Nov 6, 2026). A filter is counted once per distinct UV-filtering substance (nano and non-nano forms, and salt and acid forms, count once), including zinc oxide and titanium dioxide. A filter counts as permitted only if it is positive-listed for leave-on skin sunscreen, with or without a concentration cap, and in force on the snapshot date. Banned, NDA-only, proposed-only, “Uncertain”, “Not verified” and “See note” entries are not counted. The US count is as of the bemotrizinol final order’s effective date (Aug 9, 2026): 16 before the order, 17 after; PABA and trolamine salicylate are removed by FDA Final Order OTC000008-1 effective Sep 11, 2027 unless disputed, leaving 15. Counts were checked against each regulator’s list or, where the primary table could not be accessed (Australian determination text, China Table 5, Korea Annex 2), against TGA Table 9, regulator summaries or secondary texts. Sources: (EU Annex VI, UK Annex 6, Korea MFDS Appendix 2, Japan Standards for Cosmetics Appendix 4, Australia TGA Permissible Ingredients Determination (limits checked against TGA Table 9, Aug 2025), Health Canada Primary Sunscreen Monograph, China NMPA technical specification, Brazil RDC 600/2022, India IS 4707). Regulatory pathways differ: the US regulates sunscreens as OTC drugs, Japan as quasi-drugs and cosmetic standards, Australia as therapeutic goods, and the EU as cosmetics. Cells marked Not verified have not yet been checked against the regulator’s list. Japan’s count is 35: the 34 entries of Appendix 4 (BP-4 and its sodium salt BP-5 count once) plus zinc oxide and titanium dioxide, which Appendix 4 does not list. PEG-25 PABA has no separate Japanese entry and is not counted. China’s count is 26 on the snapshot date; 4-MBC leaves China’s permitted list on Jan 1, 2027 (NMPA Announcement No. 6 of 2026), which will make it 25.

Bemotrizinol: the first new US sunscreen filter in a generation

On June 10, 2026, the FDA issued final order OTC000039 recognizing bemotrizinol (Tinosorb S / PARSOL Shield) as GRASE at up to 6% — the first new active added to the US sunscreen monograph since 1999, and the first ever cleared through the CARES Act OTC monograph order-request pathway. The order takes effect August 9, 2026. Bemotrizinol is a photostable, broad-spectrum filter used in the EU since 2000 and permitted in roughly 80 countries. It is allowed at 10% across the EU, UK, Korea, Australia, China, Brazil, and India — and has been for two decades. Its sister filter, bisoctrizole (Tinosorb M), remains pending in the US.

The short version (for journalists & citation)

As of November 2026, the world’s major regulators permit very different sets of sunscreen UV filters. The United States — which in June 2026 approved bemotrizinol, its first new sunscreen active since 1999 — still lacks most modern UVA protection, including bisoctrizole (Tinosorb M), DHHB, and the Mexoryls, all routine in Europe and Asia. The European Union permits the broadest modern toolkit and is tightening older filters such as oxybenzone and homosalate on endocrine-activity grounds; South Korea moves fastest, adding three filters since 2024. Japan has not changed its organic-filter list since 2019. Regulators also disagree outright: 4-methylbenzylidene camphor is banned in the EU, the UK (from July 15, 2026) and, from 2027, China, yet remains legal in Korea, Australia, and Canada. Nor is the US gap limited to wealthy markets: Brazil (via a Mercosur-harmonized list) and India both permit the full modern toolkit that American consumers are only now beginning to get. The practical result is that no single sunscreen formula is legal, or optimal, in every market.

Permitted elsewhere, not in the US

The filters that define modern European and Korean sunscreens but are still missing from the US monograph even after bemotrizinol’s approval:

  • Bisoctrizole — Methylene Bis-Benzotriazolyl Tetramethylbutylphenol · 🇪🇺 🇬🇧 🇰🇷 🇯🇵 🇦🇺 🇨🇦 🇨🇳 🇧🇷 🇮🇳 Verification note (Nov 6, 2026): the UK consolidated Annex 6 was read directly on legislation.gov.uk; Australian limits were checked against TGA Table 9 (Aug 2025) rather than the determination text; China’s Table 5 and Korea’s Annex 2 could not be read as primary tables, so China and Korea are based on regulator summaries and secondary sources, and the Korea cells for 3-BC and amyl dimethyl PABA are marked Not verified. Brazil/India: ANVISA RDC 600/2022 + Mercosur GMC Res. 44/2015 & 14/2021; BIS IS 4707 (Part 4):2022 under the Cosmetics Rules 2020.
About this reference. This comparison is compiled and maintained for educational and journalistic reference by Jane Yoo, MD, a board-certified dermatologist. It summarizes complex, frequently amended regulations across ten jurisdictions and may contain simplifications or lag the very latest amendment. It is not regulatory, legal, or formulation advice — verify against the primary sources before making product, compliance, or medical decisions.
author avatar
Dr. Jane Yoo Board-Certified Dermatologist and Mohs Surgeon
Jane Yoo, MD, MPP, is a Korean American board-certified dermatologist and fellowship-trained Mohs surgeon based in Midtown Manhattan. She is a Clinical Assistant Professor at the Icahn School of Medicine at Mount Sinai and the founder of Jane Yoo MD, PLLC and the Clinical Research Center of New York. Dr. Yoo holds an undergraduate degree from MIT and a Masters of Public Policy from Harvard's Kennedy School of Government. She completed her Mohs micrographic surgery fellowship at Yale. Her clinical and research focus spans aesthetic clinical trials including injectables and laser technology, skincare formulation and sunscreen science, K-Beauty and skin of color, ultrasound guided filler dissolution, artificial intelligence and beauty tech. Dr. Yoo's research is indexed under ORCID 0000-0002-7112-8963.